M. Lind

发表

Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.

A. Boddy, R. Jackson, K. Balmanno, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.

A. Boddy, D. Newell, A. Calvert, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.

M. Tilby, D. Newell, A. Calvert, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481).

M. Millward, D. Newell, K. Balmanno, 1995, European journal of cancer.

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.

G. Rustin, N. Bleehen, E. Newlands, 1998, British Journal of Cancer.

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

A. Boddy, D. Newell, A. Calvert, 2002, European journal of cancer.

A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid

A. Boddy, S. Wedge, D. Newell, 2004, Investigational New Drugs.

The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients.

A. Hall, D. Newell, J. Sunter, 1996, British Journal of Cancer.

Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.

M. Millward, F. Chapman, A. Calvert, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.

D. Miles, I. Smith, A. Calvert, 2001, European journal of cancer.

Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene.

M. Highley, A. Boddy, J. Lunec, 1999, Seminars in oncology.

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

A. Boddy, A. Calvert, H. Thomas, 1997, British Journal of Cancer.

Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.

P. Beaune, A. Boddy, J. Idle, 1994, Biochemical pharmacology.

The role of postoperative alkylating agent therapy in early‐stage epithelial ovarian cancer

D. Crowther, C. H. Buckley, M. Lind, 1989 .

Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.

A. Boddy, D. Newell, A. Calvert, 1996, Seminars in oncology.